Humalog Mix25

Humalog Mix25 is a pre‑mixed injectable solution that contains the rapid‑acting insulin analog insulin lispro at a 25 % proportion, combined with protamine‑bound insulin lispro. It is supplied as a prescription‑only product for subcutaneous administration and is marketed in the European Union. It is designed to provide both an immediate insulin peak and a prolonged basal effect, helping patients achieve more stable glycemic control under medical supervision.

Humalog Mix25 is indicated for the management of blood glucose in adults with diabetes mellitus. It is used when a combination of rapid‑acting and intermediate‑acting insulin is appropriate.

- Type 1 diabetes mellitus requiring mealtime insulin coverage. - Type 2 diabetes mellitus inadequately controlled with oral agents alone. - Situations where a single injection can replace separate rapid‑acting and basal insulin doses. - Patients who benefit from a predictable 25 % rapid‑acting component and 75 % protamine‑bound component. - Use during pregnancy only when the potential benefit outweighs risk, as determined by a healthcare professional.

Adverse reactions to Humalog Mix25 may vary in frequency and severity.

Common: - Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient. - Injection site reactions such as redness, swelling, or itching. - Lipodystrophy, including localized lipoatrophy or lipohypertrophy at the injection site. - Transient weight gain associated with improved glycemic control.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness). - Allergic reactions ranging from urticaria to anaphylaxis. - Edema or heart failure exacerbation in susceptible individuals.

Before initiating Humalog Mix25, healthcare providers should assess several safety considerations to minimize risks.

- Verify the patient’s diagnosis (type 1 or type 2 diabetes) and need for a mixed insulin regimen. - Review history of hypoglycemia, especially severe episodes or impaired awareness. - Assess renal and hepatic function, as reduced clearance can prolong insulin action. - Consider cardiovascular status; edema or heart failure may be worsened by insulin therapy. - Evaluate pregnancy or lactation status; use only if benefits outweigh potential risks. - Ensure proper injection technique and rotation of sites to prevent lipodystrophy.

Humalog Mix25 can interact with other medicines, affecting blood glucose levels or insulin action.

Avoid: - Concomitant use of other rapid‑acting insulins or high‑dose insulin secretagogues, which may cause severe hypoglycemia. - Beta‑blockers that mask hypoglycemia symptoms and may blunt the adrenergic response.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase insulin release, requiring dose adjustments. - Corticosteroids or other agents that raise blood glucose, potentially necessitating higher insulin doses. - Alcohol consumption, especially in excess, which can cause unpredictable glucose fluctuations. - Thyroid hormones (e.g., levothyroxine) that may alter insulin requirements.